ArticleFrontiers in cell and developmental biology2021
miR-371b-5p-Engineered Exosomes Enhances Tumor Inhibitory Effect.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- miR-423-5p-enriched small extracellular vesicles drive periodontal regeneration via Sfrp2+ cell expansion.Bioactive materials · 2026Article
- A Putative Hsa-miR-582-5p-CD81 Relationship Identified by Integrative Transcriptomic Analysis in Osteosarcoma.International journal of molecular sciences · 2026Article
- MiRNA-based drugs: challenges and delivery strategies.Applied microbiology and biotechnology · 2025Review
- Hydrogels as Suitable miRNA Delivery Systems: A Review.Polymers · 2025Review
- From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment.Frontiers in immunology · 2025Review
- MiR-371b-5p reduces osteosarcoma cell migration and proliferation to induce apoptosis by targeting FUT4.Journal of Cancer · 2025Article
- Suppression of gastric cancer cell proliferation by miR-494-3p inhibitor-loaded engineered exosomes.Heliyon · 2024Article
- MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics.Biological procedures online · 2024Review
- Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma.Neuro-oncology · 2024Article
- Role of non-coding RNA in exosomes for the diagnosis and treatment of osteosarcoma.Frontiers in oncology · 2024Review
- Engineered exosomes in emerging cell-free therapy.Frontiers in oncology · 2024Review
- Silencing FUT4 Inhibits the Progression of Osteosarcoma through Activation of FOXO1.Current pharmaceutical design · 2024Article
- Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy.Research (Washington, D.C.) · 2024Review
- Methods of miRNA delivery and possibilities of their application in neuro-oncology.Non-coding RNA research · 2023Review
- Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma.Bioengineered · 2023Review
- Exosomes: Diagnostic and Therapeutic Implications in Cancer.Pharmaceutics · 2023Review
- Review
- Engineered exosomes from different sources for cancer-targeted therapy.Signal transduction and targeted therapy · 2023Review
- Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer.Cancers · 2023Article
- Small extracellular vesicles in breast cancer brain metastasis and the prospect of clinical application.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.